Review on the association of Group B Streptococcus capsular antibody and protection against invasive disease in infants

Expert Review of Vaccines

Volumn 14, Issue 1, 2014, Pages 135-149

  Dangor, Ziyaad ^a   Kwatra, Gaurav ^a   Izu, Alane ^a   Lala, Sanjay G ^b   Madhi, Shabir A ^a,c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

capsular antibodies; GBS; infants; sero correlates; vaccine

Indexed keywords

BACTERIUM ANTIBODY; GROUP B STREPTOCOCCUS CAPSULAR ANTIBODY; STREPTOCOCCUS VACCINE; TRIVALENT GROUP B STREPTOCOCCUS POLYSACCHARIDE PROTEIN CONJUGATE VACCINE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

BACTERIAL COLONIZATION; DISEASE ASSOCIATION; GROUP B STREPTOCOCCAL INFECTION; HUMAN; INFANT; INFECTION PREVENTION; META ANALYSIS (TOPIC); MOTHER; NONHUMAN; PREGNANT WOMAN; REVIEW; STREPTOCOCCUS AGALACTIAE; SYSTEMATIC REVIEW (TOPIC); BACTERIAL CAPSULE; FEMALE; IMMUNOLOGICAL TECHNIQUE; IMMUNOLOGY; NEWBORN; PREGNANCY; STANDARDS; STREPTOCOCCAL INFECTIONS;

ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; BIOLOGICAL MARKERS; FEMALE; HUMANS; IMMUNOLOGIC TECHNIQUES; INFANT; INFANT, NEWBORN; PREGNANCY; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 84917736042     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.953939     Document Type: Review

References (83)

1. Weston EJ, Pondo T, Lewis MM, et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005-2008. Pediatr Infect Dis J 2011;30(11):937-41
2. Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011;364(21):2016-25
3. Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine 2013;31(Suppl 4):D20-6
4. Johri AK, Lata H, Yadav P, et al. Epidemiology of Group B Streptococcus in developing countries. Vaccine 2013; 31(Suppl 4):D43-5
5. Montagu D, Yamey G, Visconti A, et al. Where do poor women in developing countries give birth? A multi-country analysis of demographic and health survey data. PLoS One 2011;6(2):e17155
6. Edwards MS, Gonik B. Preventing the broad spectrum of perinatal morbidity and mortality through group B streptococcal vaccination. Vaccine 2013;31(Suppl 4): D66-71
7. Madhi SA, Dangor Z, Heath PT, et al. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of earlyand late-onset invasive disease in young-infants. Vaccine 2013;31(Suppl 4): D52-7
8. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009; 27(Suppl 2):B112-16
9. World Health Organization Immunization Vaccines and Biologicals. Measuring impact of Streptococcus pneumoniae and Haemophilus influenzae type b conjugate vaccination. Expanded Programme on Immunization (EPI) of the Department of Immunization, Vaccines and Biologicals, Geneva, Switzerland. 2012;p. 36
10. The European Agency for the Evaluation of Medicinal Products. Note for the guidance on harmonisation of requirements for influenza vaccines. European Medicines Agency, London, UK. 1997;15-8
11. Hirji KF, Mehta CR, Patel NR. Computing Distributions for Exact Logistic Regression. Journal of american statistical association 1987;82(400):1110-17
12. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3): 177-88
13. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976; 294(14):753-6
14. Baker CJ, Kasper DL, Tager I, et al. Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. J Clin Invest 1977;59(5):810-18
15. Baker CJ, Kasper DL. Immunological investigation of infants with septicemia or meningitis due to group B Streptococcus. J Infect Dis 1977;136:104.S98-104
16. Wilkinson HW. Detection of group B streptococcal antibodies in human sera by radioimmunoassay: concentrations of type-specific antibodies in sera of adults and infants infected with group B streptococci. J Clin Microbiol 1978;7(2):194-201
17. Christensen KK, Christensen P, Dahlander K, et al. Quantitation of serum antibodies to surface antigens of group B streptococci types Ia, Ib, and III: low antibody levels in mothers of neonatally infected infants. Scand J Infect Dis 1980; 12(2):105-10
18. Vogel LC, Boyer KM, Gadzala CA, Gotoff SP. Prevalence of type-specific group B streptococcal antibody in pregnant women. J Pediatr 1980;96(6):1047-51
19. Baker CJ, Edwards MS, Kasper DL. Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics 1981;68(4):544-9
20. Christensen KK, Christensen P, Lindberg A, Linden V. Mothers of infants with neonatal group B streptococcal septicemia are poor responders to bacterial carbohydrate antigens. Int Arch Allergy Appl Immunol 1982;67(1):7-12
21. Klegerman ME, Boyer KM, Papierniak CK, Gotoff SP. Estimation of the protective level of human IgG antibody to the type-specific polysaccharide of group B Streptococcus type Ia. J Infect Dis 1983;148(4):648-55
22. Gotoff SP, Papierniak CK, Klegerman ME, Boyer KM. Quantitation of IgG antibody to the type-specific polysaccharide of group B streptococcus type 1b in pregnant women and infected infants. J Pediatr 1984;105(4): 628-30
23. Gray BM, Pritchard DG, Dillon HC Jr. Seroepidemiological studies of group B Streptococcus type II. J Infect Dis 1985; 151(6):1073-80
24. Gotoff SP, Odell C, Papierniak CK, et al. Human IgG antibody to group b Streptococcus type III: comparison of protective levels in a murine model with levels in infected human neonates. J Infect Dis 1986;153(3):511-19
25. Feldman RG, Ferrante A. Prevalence of anti-group B streptococcal type III capsular IgG antibodies in the United Kingdom and an analysis of their specific IgG subclasses. J Infect Dis 1990;162(4):883-7
26. Gray BM, Egan ML, Pritchard DG. The group B streptococci: from natural history to the specificity of antibodies. Semin Perinatol 1990;14(4 Suppl 1):10-21
27. Lin FY, Philips JB 3rd, Azimi PH, et al. Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study. J Infect Dis 2001;184(8):1022-8
28. Lin FY, Weisman LE, Azimi PH, et al. Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. J Infect Dis 2004;190(5):928-34
29. Matsubara K, Katayama K, Baba K, et al. Seroepidemiologic studies of serotype VIII group B Streptococcus in Japan. J Infect Dis 2002;186(6):855-8
30. Baker CJ, Carey VJ, Rench MA, et al. Maternal antibody at delivery protects neonates from early-onset group B streptococcal disease. J Infect Dis 2013;doi; 10.1093/infdis/jit549. [Epub ahead of print
31. Beachler CW, Baker CJ, Kasper DL, et al. Group B streptococcal colonization and antibody status in lower socioeconomic parturient women. Am J Obstet Gynecol 1979;133(2):171-3
32. Cleat PH, Ross J, Needham JR. Antibody levels in mothers colonised with group B streptococci during pregnancy and in their newborn infants, as measured by an enzyme linked immunosorbent assay. Med Microbiol Immunol (Berl) 1980;168(1): 49-53
33. Baker CJ, Webb BJ, Kasper DL, et al. The natural history of group B streptococcal colonization in the pregnant woman and her offspring. II. Determination of serum antibody to capsular polysaccharide from type III, group B Streptococcus. Am J Obstet Gynecol 1980;137(1):39-42
34. Christensen KK, Christensen P, Juldorf F, Dahlander K. Quantitation of antibodies against group B streptococci, Types Ia, Ib and III in sera from different groups of individuals: high antibody levels in sera from venereal disease clinic patients. Scand J Infect Dis 1981;13(3):165-9
35. Linden V, Christensen KK, Christensen P. Type-specific serum antibodies against group B streptococci among pregnant women: relation to urogenital carriage and age. Scand J Infect Dis 1982;14(3):189-93
36. Anthony BF, Concepcion NF, Wass CA, Heiner DC. Immunoglobulin G and M composition of naturally occurring antibody to type III group B streptococci. Infect Immun 1984;46(1):98-104
37. Skidmore AG, Henry DA, Smith A. Prevalence of type-specific group B streptococcal antibody in human sera: a study of 405 pregnant women. Am J Obstet Gynecol 1985;152(7 Pt 1):857-60
38. Sugiyama M, Kojima M, Ito Y, et al. [Detection of type-specific group B streptococcal antibody by indirect immunofluorescence and prevention of vertical transmission by antibiotic therapy]. Nihon Sanka Fujinka Gakkai zasshi 1987; 39(2):181-8
39. Gray BM, Dillon HC, Jr, Pritchard DG, et al. Type-specific antibodies against group B streptococci in human serum, saliva and vaginal secretions. Adv Exp Med Biol 1987;216B:995-1003
40. Gray BM, Pritchard DG, Springfield JD, et al. Seroepidemiology of group B Streptococcus type II antibody specificity. Epidemiol Infect 1988;101(2):347-54
41. Gray BM, Pritchard DG, Dillon HC Jr. Seroepidemiology of group B streptococcus type III colonization at delivery. J Infect Dis 1989;159(6):1139-42
42. Kubota T, Takada M. [Antibodies to group B streptococci in maternal and cord sera]. Nihon Sanka Fujinka Gakkai zasshi 1989; 41(6):676-82
43. Ratei R, Kainer F, Hahn H. Quantitative measurement of group B streptococcal antibodies (serotypes Ia, Ib, II and III) in human cord sera by the indirect enzyme-linked immunosorbent assay. Zentralblatt fur Bakteriologie 1990;274(2): 227-38
44. Sugiyama M, Kojima M, Yasuda Y, et al. [Quantitation of IgG antibodies to type Ia group B streptococcal type-specific polysaccharides measured by enzyme-linked immunosorbent assay]. Kansenshogaku zasshi 1990;64(7):840-6
45. Sugiyama M, Kojima M, Hori Y, et al. [Type-specific antibody to type Ia, Ib, II and III group B Streptococcus in maternal and neonatal sera measured by ELISA]. Kansenshogaku zasshi 1990;64(9):1232-8
46. Ooe Y, Nishiyama Y, Sugiyama A, et al. [ELISA for type-specific group B streptococcal antibody and its clinical significance]. Kansenshogaku zasshi 1990; 64(10):1251-4
47. Boyer KM, Klegerman ME, Gotoff SP. Development of IgM antibody to group B Streptococcus type III in human infants. J Infect Dis 1992;165(6):1049-55
48. Lagergard T, Thiringer K, Wassen L, et al. Isotype composition of antibodies to streptococcus group B type III polysaccharide and to tetanus toxoid in maternal, cord blood sera and in breast milk. Eur J Pediatr 1992;151(2):98-102
49. Hordnes K, Tynning T, Kvam AI, et al. Colonization in the rectum and uterine cervix with group B streptococci may induce specific antibody responses in cervical secretions of pregnant women. Infect Immun 1996;64(5):1643-52
50. Hoshina K. Minimization of the number of pregnant women to be treated with preventive procedure against GBS infection by means of antibody measurement. GBS Infection Group. Acta Paediatr Jpn 1997; 39(5):546-9
51. Shen X, Yang Y, Zhang J, et al. Prevalence of antibodies against group B streptococcal capsular polysaccharides in healthy Chinese neonates. Pediatr Infect Dis J 1997;16(12): 1179-80
52. Berg S, Kasvi S, Trollfors B, et al. Antibodies to group B streptococci in neonates and infants. Eur J Pediatr 1998; 157(3):221-4
53. Suara RO, Adegbola RA, Mulholland EK, et al. Seroprevalence of antibodies to group B streptococcal polysaccharides in Gambian mothers and their newborns. J Natl Med Assoc 1998;90(2):109-14
54. Mikamo H, Higa M, Sato Y, et al. Preventive procedures against GBS infection by means of antibody measurement. Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi 2000;11(1):33-7
55. Campbell JR, Hillier SL, Krohn MA, et al. Group B streptococcal colonization and serotype-specific immunity in pregnant women at delivery. Obstet Gynecol 2000; 96(4):498-503
56. Davies HD, Adair C, Mcgeer A, et al. Antibodies to capsular polysaccharides of group B Streptococcus in pregnant Canadian women: relationship to colonization status and infection in the neonate. J Infect Dis 2001;184(3):285-91
57. Matsubara K, Katayama K, Baba K, et al. Prevalence of group B streptococcal type VI capsular IgG antibodies in Japan. Eur J Clin Microbiol Infect Dis 2003;22(7):453-4
58. Terakubo S, Ichiman Y, Takemura H, et al. [Serotypes and antibody levels of group B streptococci in pregnant women]. Kansenshogaku zasshi 2003;77(3):121-6
59. Lancefield RC, Freimer EH. Type-specific polysaccharide antigens of group B streptococci. J Hyg (Lond) 1966;64(2): 191-203
60. Lancefield RC, Mccarty M, Everly WN. Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens. J Exp Med 1975; 142(1):165-79
61. Stewardson-Krieger PB, Albrandt K, Nevin T, et al. Perinatal immunity to group B beta-hemolytic streptococcus type Ia. J Infect Dis 1977;136(5):649-54
62. Kane JA, Karakawa WW. Existence of multiple immunodeterminants in the type-specific capsular substance of group B type Ia streptococci. Infect Immun 1978; 19(3):983-91
63. Baltimore RS, Kasper DL, Vecchitto J. Mouse protection test for group B Streptococcus type III. J Infect Dis 1979; 140(1):81-8
64. Cleat PH, Coid CR. Protection of mice against group B Streptococcus type Ia by IgG components of a rabbit antiserum. Med Microbiol Immunol (Berl) 1980;169(1): 9-14
65. Baltimore RS, Baker CJ, Kasper DL. Antibody to group B Streptococcus type III in human sera measured by a mouse protection test. Infect Immun 1981;32(1): 56-61
66. Fleming DO. Mouse protection assay for group B streptococcus type III. Infect Immun 1982;35(1):240-7
67. De Cueninck BJ, Eisenstein TK, Mcintosh TS, et al. Type-specific protection of neonatal rats from lethal group B streptococcal infection by immune sera obtained from human volunteers vaccinated with type III-specific polysaccharide. Infect Immun 1982;37(3):961-5
68. Fischer GW, Hunter KW, Wilson SR. Modified human immune serum globulin for intravenous administration: in vitro opsonic activity and in vivo protection against group B streptococcal disease in suckling rats. Acta Paediatr Scand 1982; 71(4):639-44
69. Larsen JW Jr, Harper JS III, London WT, et al. Antibody to type III group B Streptococcus in the rhesus monkey. Am J Obstet Gynecol 1983;146(8):958-62
70. Boyer KM, Kendall LS, Papierniak CK, et al. Protective levels of human immunoglobulin G antibody to group B streptococcus type Ib. Infect Immun 1984; 45(3):618-24
71. Christensen KK, Christensen P, Duc G, et al. Human IgG antibodies to carbohydrate and protein antigens in mouse protection tests with group B streptococci. Pediatr Res 1984;18(5):478-82
72. Hemming VG, London WT, Curfman BL, et al. Maternal humoral immunity and neonatal GBS infection: studies in a primate model. Antibiot Chemother 1985;35: 194-200
73. Ichiman Y, Yoshida K. Passive protection by human sera in mice against challenge with strains of group B streptococci. Med Microbiol Immunol (Berl) 1986;175(6): 355-62
74. Guttormsen HK, Baker CJ, Edwards MS, et al. Quantitative determination of antibodies to type III group B streptococcal polysaccharide. J Infect Dis 1996;173(1): 142-50
75. Polin RA, Douglas SD, Kasper DL, Baker CJ. Enzyme-linked immunosorbent assay for measurement of antibody to type III group B streptococci. J Clin Microbiol 1982;15(6):991-3
76. Hastings MJ, Neil J, Easmon CS. Opsonization of group B Streptococcus type III: studies using clinical strains and maternal sera. Br J Exp Pathol 1985;66(3): 317-23
77. Klesius PH, Zimmerman RA, Mathews JH, Krushak DH. Cellular and humoral immune response to group B streptococci. J Pediatr 1973;83(6):926-32
78. Hemming VG, Hall RT, Rhodes PG, et al. Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence. J Clin Invest 1976;58(6):1379-87
79. Kim KS, Wass CA, Hong JK, et al. Demonstration of opsonic and protective activity of human cord sera against type III group B streptococcus that are independent of type-specific antibody. Pediatr Res 1988; 24(5):628-32
80. Edwards MS. Complement in neonatal infections: an overview. Pediatr Infect Dis 1986;5(3 Suppl):S168-70
81. Feldman RG, Breukels MA, David S, Rijkers GT. Properties of human anti-group B streptococcal type III capsular IgG antibody. Clin Immunol Immunopathol 1998;86(2):161-9
82. Edwards MS, Lane HJ, Hillier SL, et al. Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines. Vaccine 2012;30(28):4123-6
83. Lancaster L, Saydam M, Markey K, et al. Immunogenicity and physico-chemical characterisation of a candidate conjugate vaccine against group B streptococcus serotypes Ia, Ib and III. Vaccine 2011; 29(17):3213-21